Thus, another prospective strategy is to combine immune-oncology agents with other immune-modulating elements in which exosomal miRNA might play a synergic role in immunotherapy; for example, the inhibition of miR-23a-3p or miR-126a-5p, or both, in cancer cells could prevent its exosomal release and thus the consequent macrophage PD-L1 expression [70]. Here, CD274 is linked to cancer.